- New ETFs
- Bond ETFs
- Currency ETFs
- Emerging Market ETFs
- Commodity ETFs
- Broad U.S. Equity ETFs
- Sector ETFs
- Specialty ETFs
Pete Najarian Is Watching Medivation (MDVN)
Recent Articles by Craig Jones
- Jim Cramer's Lightning Round Picks (APD, WEN, MCD, TSRA, VSI, VITC, PTV, IP, STXS, ABT, NMM, ATPG, GMCR)
- Fast Money Picks For March 22nd (MHS, CVS)
- Benzinga's Top ETF Decliners (AGQ, EDC, TNA, DGP)
- Benzinga's Top ETF Gainers (ZSL, TZA, EDZ, DTO)
- Guy Adami Likes TIF
CNBC
- General Growth Properties (GGP) Is Back In Favor
- Jim Cramer's Lightning Round Picks (APD, WEN, MCD, TSRA, VSI, VITC, PTV, IP, STXS, ABT, NMM, ATPG, GMCR)
- Fast Money Picks For March 22nd (MHS, CVS)
- Cramer Recommends Sonus Networks As A Speculative Play (SONS)
- Guy Adami Likes TIF
Long Ideas
- General Growth Properties (GGP) Is Back In Favor
- Jim Cramer's Lightning Round Picks (APD, WEN, MCD, TSRA, VSI, VITC, PTV, IP, STXS, ABT, NMM, ATPG, GMCR)
- Fast Money Picks For March 22nd (MHS, CVS)
- Cramer Recommends Sonus Networks As A Speculative Play (SONS)
- Biotech Stock Mailbag: Generex (PFE, MNKD)
Fast Money
- General Growth Properties (GGP) Is Back In Favor
- Fast Money Picks For March 22nd (MHS, CVS)
- Guy Adami Likes TIF
- Jon Najarian Is Watching Smithfield Foods, Inc. (SFD)
- Guy Adami Is Bearish On PALM
Trading Ideas
- Jim Cramer's Lightning Round Picks (APD, WEN, MCD, TSRA, VSI, VITC, PTV, IP, STXS, ABT, NMM, ATPG, GMCR)
- Fast Money Picks For March 22nd (MHS, CVS)
- Cramer Recommends Sonus Networks As A Speculative Play (SONS)
- Carter Worth Says Best Buy Losing Momentum (BBY)
- Biotech Stock Mailbag: Generex (PFE, MNKD)
Media
- Jim Cramer's Lightning Round Picks (APD, WEN, MCD, TSRA, VSI, VITC, PTV, IP, STXS, ABT, NMM, ATPG, GMCR)
- Fast Money Picks For March 22nd (MHS, CVS)
- Pressure Mounts On EU To Create A System To Handle Failure Of Large Banks
- Lowe’s (LOW) Could See Faster Growth Than Rival; Barron’s
- Dr Pepper (DPS) Pouring Out Sweet Returns For Investors; Barron’s
Posted on 02/08/10 at 7:35pm by Craig Jones
CNBC Fast Money's Pete Najarian is thinking about Medivation, Inc. (NASDAQ: MDVN), a biotech company that is working on a new drug in a partnership with Pfizer (NYSE: PFE).
He said that MDVN has a drug that is in the third phase of research and its results are expected in March. The drug is called Dimebon and it may help patients with Alzheimer's disease and Huntington disease.
The second phase was really successful, but Pete Najarian is still careful because he knows that these kind of trades can either be a hit or a miss.
One way to make this trade is through Pfizer (PFE). Medivation (MDVN) fell 1.75% today and Pfizer (PFE) dropped 0.67%
Bookmark/Search this post with:
Related Articles
Today's Trading Ideas
Featured Articles
Related News from the Stock Market
There are 0 comments
Please note that comments may take up to one hour before they get published on the site. Please check back later to see your comments.
Post new comment
Receive Benzinga's Best 2010 Stock Idea!
